Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19
The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-con...
Saved in:
Published in | Chemico-biological interactions Vol. 331; p. 109282 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier B.V
01.11.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-consuming and cannot be relied on as a solution in combatting the immediate global challenge. In such a situation, the drug repurposing becomes an attractive solution to identify the potential of COVID-19 treatment by existing drugs, which are approved for other indications. Here, we review the potential use of rapamycin, an mTOR (Mammalian Target of Rapamycin) inhibitor that can be repurposed at low dosages for the treatment of COVID-19. Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10. Overall, the use of rapamycin can help to control viral particle synthesis, cytokine storms and contributes to fight the disease by its anti-aging and anti-obesity effects. Since, rapamycin targets the host factors and not viral machinery, it represents a potent candidate for the treatment of COVID-19 than antiviral drugs as its efficacy is less likely to be dampened with high mutation rate of viral RNA. Additionally, the inhibitory effect of rapamycin on cell proliferation may aid in reducing viral replication. Therefore, by drug repurposing, low dosages of rapamycin can be tested for the potential treatment of COVID-19/SARS-CoV-2 infection.
[Display omitted]
•Rapamycin, an mTOR inhibitor can be repurposed for treatment of COVID-19.•Rapamycin inhibits protein synthesis, pro-inflammatory cytokines and delays aging.•Rapamycin action targeted on host factors and not viral machinery.•Rapamycin act on cell proliferation may aid in reducing viral replication. |
---|---|
AbstractList | The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-consuming and cannot be relied on as a solution in combatting the immediate global challenge. In such a situation, the drug repurposing becomes an attractive solution to identify the potential of COVID-19 treatment by existing drugs, which are approved for other indications. Here, we review the potential use of rapamycin, an mTOR (Mammalian Target of Rapamycin) inhibitor that can be repurposed at low dosages for the treatment of COVID-19. Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10. Overall, the use of rapamycin can help to control viral particle synthesis, cytokine storms and contributes to fight the disease by its anti-aging and anti-obesity effects. Since, rapamycin targets the host factors and not viral machinery, it represents a potent candidate for the treatment of COVID-19 than antiviral drugs as its efficacy is less likely to be dampened with high mutation rate of viral RNA. Additionally, the inhibitory effect of rapamycin on cell proliferation may aid in reducing viral replication. Therefore, by drug repurposing, low dosages of rapamycin can be tested for the potential treatment of COVID-19/SARS-CoV-2 infection.
[Display omitted]
•Rapamycin, an mTOR inhibitor can be repurposed for treatment of COVID-19.•Rapamycin inhibits protein synthesis, pro-inflammatory cytokines and delays aging.•Rapamycin action targeted on host factors and not viral machinery.•Rapamycin act on cell proliferation may aid in reducing viral replication. The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-consuming and cannot be relied on as a solution in combatting the immediate global challenge. In such a situation, the drug repurposing becomes an attractive solution to identify the potential of COVID-19 treatment by existing drugs, which are approved for other indications. Here, we review the potential use of rapamycin, an mTOR (Mammalian Target of Rapamycin) inhibitor that can be repurposed at low dosages for the treatment of COVID-19. Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10. Overall, the use of rapamycin can help to control viral particle synthesis, cytokine storms and contributes to fight the disease by its anti-aging and anti-obesity effects. Since, rapamycin targets the host factors and not viral machinery, it represents a potent candidate for the treatment of COVID-19 than antiviral drugs as its efficacy is less likely to be dampened with high mutation rate of viral RNA. Additionally, the inhibitory effect of rapamycin on cell proliferation may aid in reducing viral replication. Therefore, by drug repurposing, low dosages of rapamycin can be tested for the potential treatment of COVID-19/SARS-CoV-2 infection. Image 1 • Rapamycin, an mTOR inhibitor can be repurposed for treatment of COVID-19. • Rapamycin inhibits protein synthesis, pro-inflammatory cytokines and delays aging. • Rapamycin action targeted on host factors and not viral machinery. • Rapamycin act on cell proliferation may aid in reducing viral replication. The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-consuming and cannot be relied on as a solution in combatting the immediate global challenge. In such a situation, the drug repurposing becomes an attractive solution to identify the potential of COVID-19 treatment by existing drugs, which are approved for other indications. Here, we review the potential use of rapamycin, an mTOR (Mammalian Target of Rapamycin) inhibitor that can be repurposed at low dosages for the treatment of COVID-19. Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10. Overall, the use of rapamycin can help to control viral particle synthesis, cytokine storms and contributes to fight the disease by its anti-aging and anti-obesity effects. Since, rapamycin targets the host factors and not viral machinery, it represents a potent candidate for the treatment of COVID-19 than antiviral drugs as its efficacy is less likely to be dampened with high mutation rate of viral RNA. Additionally, the inhibitory effect of rapamycin on cell proliferation may aid in reducing viral replication. Therefore, by drug repurposing, low dosages of rapamycin can be tested for the potential treatment of COVID-19/SARS-CoV-2 infection. |
ArticleNumber | 109282 |
Author | Husain, Amjad Byrareddy, Siddappa N. |
Author_xml | – sequence: 1 givenname: Amjad surname: Husain fullname: Husain, Amjad email: amjad@iiserb.ac.in organization: Centre for Science and Society, Indian Institute of Science Education and Research (IISER), Bhopal, MP, India – sequence: 2 givenname: Siddappa N. surname: Byrareddy fullname: Byrareddy, Siddappa N. email: sid.byrareddy@unmc.edu organization: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Centre, Omaha, NE, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33031791$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kNtKAzEQhoNU7EEfwBvJC2zNZA_ZRRCkngqFgqi3IZvMtintZsluC317U6pFb7waZvL__2S-IenVrkZCroGNgUF2uxrr0o4544e-4Dk_IwPIBY-EyLMeGTDGioiLQvTJsG1XoWU8YRekH8csBlHAgMzfVKM2e21rqlqqaOM6rDur1tRjs_WNa5Eav11QrWpjjeqQVs7Tbom086i6TVBTV9HJ_HP6GEFxSc4rtW7x6ruOyMfz0_vkNZrNX6aTh1mkkxS6KMuzAoQWrNQ8NYnRKk8ZM2VSCqGBZ5imUCmVJoBhmFXA4yrjFYO8TKGMVTwi98fcZltu0OjwDa_WsvF2o_xeOmXl35faLuXC7aRI4wzC-SMCxwDtXdt6rE5eYPJAV65koCsPdOWRbvDc_F56cvzgDIK7owDD6TuLXrbaYq3RWI-6k8bZf-K_ABJejJQ |
CitedBy_id | crossref_primary_10_3389_fcimb_2023_1098712 crossref_primary_10_1093_bfgp_elab029 crossref_primary_10_1007_s13577_021_00495_2 crossref_primary_10_3390_v14020174 crossref_primary_10_1080_15384101_2024_2340859 crossref_primary_10_1002_ctd2_66 crossref_primary_10_1016_j_bbrc_2023_149354 crossref_primary_10_1016_j_mex_2021_101270 crossref_primary_10_1016_j_drudis_2021_10_002 crossref_primary_10_1038_s41598_023_31276_6 crossref_primary_10_1016_j_sjbs_2021_06_015 crossref_primary_10_1016_j_colsurfb_2021_112177 crossref_primary_10_3390_ph14030217 crossref_primary_10_1186_s13023_024_03260_4 crossref_primary_10_1515_jbcpp_2020_0495 crossref_primary_10_1016_j_molcel_2021_04_022 crossref_primary_10_1172_jci_insight_148003 crossref_primary_10_1002_rmv_2503 crossref_primary_10_1111_obr_13221 crossref_primary_10_1038_s41598_022_08073_8 crossref_primary_10_3389_fmed_2022_852973 crossref_primary_10_3389_fphar_2021_638334 crossref_primary_10_1098_rsfs_2021_0006 crossref_primary_10_1002_jbt_22795 crossref_primary_10_1371_journal_pone_0266124 crossref_primary_10_2174_1570162X1903210401104648 crossref_primary_10_6002_ect_2021_0232 crossref_primary_10_1007_s11010_021_04200_7 crossref_primary_10_1172_JCI160766 crossref_primary_10_1007_s13346_021_01102_5 crossref_primary_10_1186_s40643_022_00554_y crossref_primary_10_3389_fimmu_2022_830990 crossref_primary_10_3390_ijms24065664 crossref_primary_10_3389_fmicb_2022_850087 crossref_primary_10_1177_09636897221090259 crossref_primary_10_1002_jccs_202100079 crossref_primary_10_3748_wjg_v27_i29_4763 crossref_primary_10_1007_s11033_023_08283_x crossref_primary_10_3389_fnano_2021_644023 crossref_primary_10_1002_ccr3_4218 crossref_primary_10_1128_mbio_00862_24 crossref_primary_10_3390_biomedinformatics3040055 crossref_primary_10_1186_s13578_022_00899_z crossref_primary_10_1016_j_rmcr_2021_101505 crossref_primary_10_3389_fmicb_2022_889835 |
Cites_doi | 10.1038/nm.3595 10.1016/j.ccr.2004.06.007 10.1016/j.drudis.2007.01.004 10.1210/jc.2015-3555 10.1200/JCO.2010.34.1578 10.1128/CMR.00102-14 10.1016/j.cell.2015.02.041 10.4161/cc.5.18.3288 10.1016/j.ajpath.2012.04.018 10.3390/nu12040988 10.1038/s41421-020-0153-3 10.1016/S2213-8587(20)30183-2 10.1016/j.canlet.2015.07.012 10.1016/j.cca.2020.06.017 10.1146/annurev-nutr-071714-034355 10.1016/j.tcb.2014.03.003 10.1111/j.1600-6143.2012.04002.x 10.4049/jimmunol.144.1.251 10.1093/ndt/gfm420 10.1172/JCI37539 10.1038/nrd1468 10.1158/2159-8290.CD-13-0353 10.1139/y77-007 10.1111/j.1600-6143.2011.03473.x 10.1161/01.CIR.0000057979.36322.88 10.1038/nature08221 10.7554/eLife.11058 10.1016/j.cell.2013.05.039 10.3389/fonc.2017.00273 10.1016/j.cell.2012.07.032 10.1128/JVI.01429-16 10.1073/pnas.171076798 10.1254/jphs.08215FP 10.1038/426620a 10.4161/cc.10.12.15620 10.1016/j.ahj.2004.03.046 10.1158/2159-8290.CD-13-0929 10.1016/j.trre.2014.03.002 10.1083/jcb.jcb.200206108 10.4049/jimmunol.1203094 10.1038/onc.2011.42 10.1111/acel.12203 10.1016/j.fertnstert.2010.07.1041 10.1038/s41573-019-0036-1 10.1126/science.abc6261 10.1517/14740338.2013.752814 10.1038/cdd.2008.110 10.3389/fphys.2017.00788 10.1016/j.cell.2017.03.035 |
ContentType | Journal Article |
Copyright | 2020 Elsevier B.V. Copyright © 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. |
Copyright_xml | – notice: 2020 Elsevier B.V. – notice: Copyright © 2020 Elsevier B.V. All rights reserved. – notice: 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
DOI | 10.1016/j.cbi.2020.109282 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry Biology |
EISSN | 1872-7786 |
EndPage | 109282 |
ExternalDocumentID | 10_1016_j_cbi_2020_109282 33031791 S000927972031053X |
Genre | Journal Article Review |
GroupedDBID | --- --K --M -~X .~1 0R~ 1B1 1RT 1~. 1~5 29B 4.4 457 4G. 5GY 5RE 5VS 6J9 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AATCM AAXUO ABFRF ABFYP ABJNI ABLST ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHEUO AIEXJ AIKHN AITUG AJOXV AKIFW ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLECG BLXMC CS3 DU5 EBS EFJIC EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KCYFY KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SES SPCBC SSJ SSP SSZ T5K WH7 ~G- AKRWK CGR CUY CVF ECM EIF NPM RIG .GJ 0SF 3O- 53G AAQXK AAXKI AAYJJ AAYXX ABEFU ABFNM ABXDB ADMUD ADVLN AFFNX AHHHB AI. ASPBG AVWKF AZFZN CITATION EJD FEDTE FGOYB G-2 HMT HVGLF HZ~ H~9 NCXOZ R2- SEW SPT VH1 WUQ ZGI ZXP 5PM |
ID | FETCH-LOGICAL-c451t-686917c70bc25d4dca8500db4b77c126e551faa541edb46f123f62f018b51b3a3 |
IEDL.DBID | .~1 |
ISSN | 0009-2797 |
IngestDate | Tue Sep 17 21:23:26 EDT 2024 Thu Sep 12 18:04:17 EDT 2024 Thu May 23 23:42:49 EDT 2024 Fri Feb 23 02:41:34 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 Drug repurposing mTOR SARS-CoV-2 Rapamycin |
Language | English |
License | Copyright © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c451t-686917c70bc25d4dca8500db4b77c126e551faa541edb46f123f62f018b51b3a3 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7536130 |
PMID | 33031791 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7536130 crossref_primary_10_1016_j_cbi_2020_109282 pubmed_primary_33031791 elsevier_sciencedirect_doi_10_1016_j_cbi_2020_109282 |
PublicationCentury | 2000 |
PublicationDate | 2020-11-01 |
PublicationDateYYYYMMDD | 2020-11-01 |
PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Ireland |
PublicationPlace_xml | – name: Ireland |
PublicationTitle | Chemico-biological interactions |
PublicationTitleAlternate | Chem Biol Interact |
PublicationYear | 2020 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Saxton, Sabatini (bib29) 2017; 169 Kolosova, Muraleva, Zhdankina, Stefanova, Fursova, Blagosklonny (bib27) 2012; 181 Caron, Richard, Laplante (bib6) 2015; 35 Sargiacomo, Sotgia, Lisanti (bib55) 2020; 12 Vellai, Takacs-Vellai, Zhang, Kovacs, Orosz, Müller (bib18) 2003; 426 Poglitsch, Weichhart, Hecking, Werzowa, Katholnig, Antlanger, Krmpotic, Jonjic, Hörl, Zlabinger, Puchhammer, Säemann (bib42) 2012; 12 Di Nicolantonio, Arena, Tabernero, Grosso, Molinari, Macarulla, Russo, Cancelliere, Zecchin, Mazzucchelli, Sasazuki, Shirasawa, Geuna, Frattini, Baselga, Gallicchio, Biffo, Bardelli (bib52) 2010; 120 Foldenauer, McClellan, Berger, Hazlett (bib38) 2013; 190 Kaplan, Qazi, Wellen (bib46) 2014; 28 Strittmatter (bib2) 2014; 20 Bar-Peled, Sabatini (bib7) 2014; 24 Fang, Bartke (bib23) 2013; 5 Harrison, Strong, Sharp, Nelson, Astle, Flurkey, Nadon, Wilkinson, Frenkel, Carter, Pahor, Javors, Fernandez, Miller (bib17) 2009; 460 Sarkar, Ravikumar, Floto, Rubinsztein (bib26) 2009; 16 Grabiner, Nardi, Birsoy, Possemato, Shen, Sinha, Jordan, Beck, Sabatini (bib11) 2014; 4 Ashburn, Thor (bib1) 2004; 3 Zhou, Hou, Shen, Huang, Martin, Cheng (bib57) 2020; 6 Dai, Karunadharma, Chiao, Basisty, Crispin, Hsieh, Chen, Gu, Djukovic, Raftery, Beyer, MacCoss, Rabinovitch (bib19) 2014; 13 Wagle, Grabiner, Van Allen, Hodis, Jacobus, Supko, Stewart, Choueiri, Gandhi, Cleary, Elfiky, Taplin, Stack, Signoretti, Loda, Shapiro, Sabatini, Lander, Gabriel, Kantoff, Garraway, Rosenberg (bib12) 2014; 4 Blagosklonny (bib20) 2006; 5 Ekshyyan, Khandelwal, Rong, Moore-Medlin, Ma, Alexander, Nathan (bib40) 2016; 8 Shaw, Bardeesy, Manning, Lopez, Kosmatka, DePinho, Cantley (bib15) 2004; 6 Chan, Lau, To, Cheng, Woo, Yuen (bib5) 2015; 28 Shioi, McMullen, Tarnavski, Converso, Sherwood, Manning, Izumo (bib25) 2003; 107 Carroll, Maetzel, Maddocks, Otten, Ratcliff, Smith, Dunlop, Passos, Davies, Jaenisch, Tee, Sarkar, Korolchuk (bib48) 2016; 5 Chantranupong, Wolfson, Sabatini (bib8) 2015; 161 Mitchell (bib31) 2020; 8 Neshat, Mellinghoff, Tran, Stiles, Thomas, Petersen, Frost, Gibbons, Wu, Sawyers (bib13) 2001; 98 Weigelt, Warne, Downward (bib51) 2011; 30 Guarda, Marchant, Fajuri, Martínez, Morán, Mendez, Uriarte, Valenzuela, Lazen (bib24) 2004; 148 Grant, Lahore, McDonnell, Baggerly, French, Aliano, Bhattoa (bib32) 2020; 12 Pallet, Legendre (bib45) 2013; 12 Dumont, Staruch, Koprak, Melino, Sigal (bib10) 1990; 144 Yoon (bib53) 2017; 8 Arunachalam, Wimmers, Mok, Perera, Scott, Hagan, Sigal, Feng, Bristow, Tak-Yin Tsang, Wagh, Coller, Pellegrini, Kazmin, Alaaeddine, Leung, Chan, Chik, Choi, Huerta, Paine McCullough, Lv, Anderson, Edupuganti, Upadhyay, Bosinger, Maecker, Khatri, Rouphael, Peiris, Pulendran (bib43) 2020; 369 Husain, Hu, Sadow, Nucera (bib54) 2016; 380 Coleman, Sisk, Mingo, Nelson, White, Frieman (bib4) 2016; 90 Bonam, Wang, Muller (bib49) 2019; 18 Al-Hendy, Diamond, Boyer, Halder (bib33) 2016; 101 Lisse, Hewison (bib34) 2011; 10 Chang, Chiu, Wu, Chen, Liao, Chao, Mao (bib36) 2009; 109 Carmona, Michan (bib22) 2016; 68 Wu, Wang, Kuo, Shannar, Peter, Chou, Li, Hudlikar, Liu, Liu, Poiani, Amorosa, Brunetti, Kong (bib56) 2020 Song, Li, Xie, Hou, You (bib37) 2020; 509 Hernandez, Pryszlak, Smith, Yanchus, Kurji, Shahani, Molinski (bib3) 2017; 7 Martel, Klicius, Galet (bib9) 1977; 55 Oza, Elit, Tsao, Kamel-Reid, Biagi, Provencher, Gotlieb, Hoskins, Ghatage, Tonkin, Mackay, Mazurka, Sederias, Ivy, Dancey, Eisenhauer (bib16) 2011; 29 Weiner, Sellin, Vonend, Schenker, Buchner, Flecken, Viebahn, Rump (bib44) 2007; 22 López-Otín, Blasco, Partridge, Serrano, Kroemer (bib30) 2013; 153 Blagosklonny (bib21) 2007; 12 Chiao, Kolwicz, Basisty, Gagnidze, Zhang, Gu, Djukovic, Beyer, Raftery, MacCoss, Tian, Rabinovitch (bib28) 2016; 8 Nepomuceno, Balatoni, Natkunam, Snow, Krams, Martinez (bib39) 2003; 63 Sharan, Halder, Thota, Jaleel, Nair, Al-Hendy (bib35) 2011; 95 Ferrer, Araki, Ford (bib41) 2011; 11 Bar-Peled, Schweitzer, Zoncu, Sabatini (bib47) 2012; 150 Jaeschke, Hartkamp, Saitoh, Roworth, Nobukuni, Hodges, Sampson, Thomas, Lamb (bib14) 2002; 159 Samuels, Waldman (bib50) 2010; 347 Lisse (10.1016/j.cbi.2020.109282_bib34) 2011; 10 Bonam (10.1016/j.cbi.2020.109282_bib49) 2019; 18 Kolosova (10.1016/j.cbi.2020.109282_bib27) 2012; 181 Blagosklonny (10.1016/j.cbi.2020.109282_bib20) 2006; 5 Fang (10.1016/j.cbi.2020.109282_bib23) 2013; 5 Dai (10.1016/j.cbi.2020.109282_bib19) 2014; 13 Sarkar (10.1016/j.cbi.2020.109282_bib26) 2009; 16 Ferrer (10.1016/j.cbi.2020.109282_bib41) 2011; 11 Chan (10.1016/j.cbi.2020.109282_bib5) 2015; 28 Al-Hendy (10.1016/j.cbi.2020.109282_bib33) 2016; 101 Husain (10.1016/j.cbi.2020.109282_bib54) 2016; 380 Sharan (10.1016/j.cbi.2020.109282_bib35) 2011; 95 Nepomuceno (10.1016/j.cbi.2020.109282_bib39) 2003; 63 Weiner (10.1016/j.cbi.2020.109282_bib44) 2007; 22 Saxton (10.1016/j.cbi.2020.109282_bib29) 2017; 169 Strittmatter (10.1016/j.cbi.2020.109282_bib2) 2014; 20 Bar-Peled (10.1016/j.cbi.2020.109282_bib7) 2014; 24 Grant (10.1016/j.cbi.2020.109282_bib32) 2020; 12 Kaplan (10.1016/j.cbi.2020.109282_bib46) 2014; 28 Ekshyyan (10.1016/j.cbi.2020.109282_bib40) 2016; 8 Vellai (10.1016/j.cbi.2020.109282_bib18) 2003; 426 Shaw (10.1016/j.cbi.2020.109282_bib15) 2004; 6 Poglitsch (10.1016/j.cbi.2020.109282_bib42) 2012; 12 Samuels (10.1016/j.cbi.2020.109282_bib50) 2010; 347 Martel (10.1016/j.cbi.2020.109282_bib9) 1977; 55 López-Otín (10.1016/j.cbi.2020.109282_bib30) 2013; 153 Yoon (10.1016/j.cbi.2020.109282_bib53) 2017; 8 Chantranupong (10.1016/j.cbi.2020.109282_bib8) 2015; 161 Oza (10.1016/j.cbi.2020.109282_bib16) 2011; 29 Sargiacomo (10.1016/j.cbi.2020.109282_bib55) 2020; 12 Blagosklonny (10.1016/j.cbi.2020.109282_bib21) 2007; 12 Carmona (10.1016/j.cbi.2020.109282_bib22) 2016; 68 Weigelt (10.1016/j.cbi.2020.109282_bib51) 2011; 30 Caron (10.1016/j.cbi.2020.109282_bib6) 2015; 35 Grabiner (10.1016/j.cbi.2020.109282_bib11) 2014; 4 Chiao (10.1016/j.cbi.2020.109282_bib28) 2016; 8 Shioi (10.1016/j.cbi.2020.109282_bib25) 2003; 107 Hernandez (10.1016/j.cbi.2020.109282_bib3) 2017; 7 Mitchell (10.1016/j.cbi.2020.109282_bib31) 2020; 8 Carroll (10.1016/j.cbi.2020.109282_bib48) 2016; 5 Ashburn (10.1016/j.cbi.2020.109282_bib1) 2004; 3 Harrison (10.1016/j.cbi.2020.109282_bib17) 2009; 460 Di Nicolantonio (10.1016/j.cbi.2020.109282_bib52) 2010; 120 Wagle (10.1016/j.cbi.2020.109282_bib12) 2014; 4 Neshat (10.1016/j.cbi.2020.109282_bib13) 2001; 98 Coleman (10.1016/j.cbi.2020.109282_bib4) 2016; 90 Dumont (10.1016/j.cbi.2020.109282_bib10) 1990; 144 Arunachalam (10.1016/j.cbi.2020.109282_bib43) 2020; 369 Wu (10.1016/j.cbi.2020.109282_bib56) 2020 Bar-Peled (10.1016/j.cbi.2020.109282_bib47) 2012; 150 Guarda (10.1016/j.cbi.2020.109282_bib24) 2004; 148 Foldenauer (10.1016/j.cbi.2020.109282_bib38) 2013; 190 Chang (10.1016/j.cbi.2020.109282_bib36) 2009; 109 Zhou (10.1016/j.cbi.2020.109282_bib57) 2020; 6 Jaeschke (10.1016/j.cbi.2020.109282_bib14) 2002; 159 Pallet (10.1016/j.cbi.2020.109282_bib45) 2013; 12 Song (10.1016/j.cbi.2020.109282_bib37) 2020; 509 |
References_xml | – volume: 63 start-page: 4472 year: 2003 end-page: 4480 ident: bib39 article-title: Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas publication-title: Canc. Res. contributor: fullname: Martinez – volume: 380 start-page: 577 year: 2016 end-page: 585 ident: bib54 article-title: Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E) publication-title: Canc. Lett. contributor: fullname: Nucera – volume: 30 start-page: 3222 year: 2011 end-page: 3233 ident: bib51 article-title: PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs publication-title: Oncogene contributor: fullname: Downward – volume: 460 start-page: 392 year: 2009 end-page: 395 ident: bib17 article-title: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice publication-title: Nature contributor: fullname: Miller – volume: 3 start-page: 673 year: 2004 end-page: 683 ident: bib1 article-title: Drug repositioning: identifying and developing new uses for existing drugs publication-title: Nat. Rev. Drug Discov. contributor: fullname: Thor – volume: 95 start-page: 247 year: 2011 end-page: 253 ident: bib35 article-title: Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase publication-title: Fertil. Steril. contributor: fullname: Al-Hendy – volume: 98 start-page: 10314 year: 2001 end-page: 10319 ident: bib13 article-title: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR publication-title: Proc. Natl. Acad. Sci. U. S. A. contributor: fullname: Sawyers – volume: 28 start-page: 126 year: 2014 end-page: 133 ident: bib46 article-title: Strategies for the management of adverse events associated with mTOR inhibitors publication-title: Transplant. Rev. contributor: fullname: Wellen – volume: 4 start-page: 546 year: 2014 end-page: 553 ident: bib12 article-title: Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib publication-title: Canc. Discov. contributor: fullname: Rosenberg – volume: 12 start-page: 177 year: 2013 end-page: 186 ident: bib45 article-title: Adverse events associated with mTOR inhibitors publication-title: Expet Opin. Drug Saf. contributor: fullname: Legendre – volume: 107 start-page: 1664 year: 2003 end-page: 1670 ident: bib25 article-title: Rapamycin attenuates load-induced cardiac hypertrophy in mice publication-title: Circulation contributor: fullname: Izumo – volume: 8 start-page: 570 year: 2020 ident: bib31 article-title: Vitamin-D and COVID-19: do deficient risk a poorer outcome? publication-title: Lancet Diabetes Endocrinol. contributor: fullname: Mitchell – volume: 8 start-page: 314 year: 2016 end-page: 327 ident: bib28 article-title: Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts publication-title: Aging (N Y) contributor: fullname: Rabinovitch – volume: 12 start-page: 6511 year: 2020 end-page: 6517 ident: bib55 article-title: COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? publication-title: Aging (N Y) contributor: fullname: Lisanti – volume: 347 start-page: 21 year: 2010 end-page: 41 ident: bib50 article-title: Oncogenic mutations of PIK3CA in human cancers publication-title: Curr. Top. Microbiol. Immunol. contributor: fullname: Waldman – volume: 8 start-page: 788 year: 2017 ident: bib53 article-title: mTOR as a key regulator in maintaining skeletal muscle mass publication-title: Front. Physiol. contributor: fullname: Yoon – volume: 22 start-page: 3631 year: 2007 end-page: 3637 ident: bib44 article-title: Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature publication-title: Nephrol. Dial. Transplant. contributor: fullname: Rump – volume: 5 year: 2016 ident: bib48 article-title: Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity publication-title: Elife contributor: fullname: Korolchuk – volume: 169 start-page: 361 year: 2017 end-page: 371 ident: bib29 article-title: mTOR signaling in growth, metabolism, and disease publication-title: Cell contributor: fullname: Sabatini – volume: 12 year: 2020 ident: bib32 article-title: Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths publication-title: Nutrients contributor: fullname: Bhattoa – volume: 11 start-page: 654 year: 2011 end-page: 659 ident: bib41 article-title: Paradoxical aspects of rapamycin immunobiology in transplantation publication-title: Am. J. Transplant. contributor: fullname: Ford – volume: 35 start-page: 321 year: 2015 end-page: 348 ident: bib6 article-title: The roles of mTOR complexes in lipid metabolism publication-title: Annu. Rev. Nutr. contributor: fullname: Laplante – volume: 6 start-page: 14 year: 2020 ident: bib57 article-title: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 publication-title: Cell Discov. contributor: fullname: Cheng – volume: 29 start-page: 3278 year: 2011 end-page: 3285 ident: bib16 article-title: Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group publication-title: J. Clin. Oncol. contributor: fullname: Eisenhauer – volume: 90 start-page: 8924 year: 2016 end-page: 8933 ident: bib4 article-title: Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion publication-title: J. Virol. contributor: fullname: Frieman – volume: 181 start-page: 472 year: 2012 end-page: 477 ident: bib27 article-title: Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats publication-title: Am. J. Pathol. contributor: fullname: Blagosklonny – volume: 161 start-page: 67 year: 2015 end-page: 83 ident: bib8 article-title: Nutrient-sensing mechanisms across evolution publication-title: Cell contributor: fullname: Sabatini – volume: 144 start-page: 251 year: 1990 end-page: 258 ident: bib10 article-title: Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin publication-title: J. Immunol. contributor: fullname: Sigal – volume: 4 start-page: 554 year: 2014 end-page: 563 ident: bib11 article-title: A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity publication-title: Canc. Discov. contributor: fullname: Sabatini – volume: 120 start-page: 2858 year: 2010 end-page: 2866 ident: bib52 article-title: Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus publication-title: J. Clin. Invest. contributor: fullname: Bardelli – start-page: 1 year: 2020 end-page: 15 ident: bib56 article-title: An update on current therapeutic drugs treating COVID-19 publication-title: Curr. Pharmacol. Rep. contributor: fullname: Kong – volume: 369 start-page: 1210 year: 2020 end-page: 1220 ident: bib43 article-title: Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans publication-title: Science contributor: fullname: Pulendran – volume: 150 start-page: 1196 year: 2012 end-page: 1208 ident: bib47 article-title: Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1 publication-title: Cell contributor: fullname: Sabatini – volume: 509 start-page: 280 year: 2020 end-page: 287 ident: bib37 article-title: Cytokine storm induced by SARS-CoV-2 publication-title: Clin. Chim. Acta contributor: fullname: You – volume: 153 start-page: 1194 year: 2013 end-page: 1217 ident: bib30 article-title: The hallmarks of aging publication-title: Cell contributor: fullname: Kroemer – volume: 5 start-page: 2087 year: 2006 end-page: 2102 ident: bib20 article-title: Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition publication-title: Cell Cycle contributor: fullname: Blagosklonny – volume: 10 start-page: 1888 year: 2011 end-page: 1889 ident: bib34 article-title: Vitamin D: a new player in the world of mTOR signaling publication-title: Cell Cycle contributor: fullname: Hewison – volume: 8 start-page: 4822 year: 2016 end-page: 4830 ident: bib40 article-title: Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells publication-title: Am. J. Trans. Res. contributor: fullname: Nathan – volume: 20 start-page: 590 year: 2014 end-page: 591 ident: bib2 article-title: Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks publication-title: Nat. Med. contributor: fullname: Strittmatter – volume: 13 start-page: 529 year: 2014 end-page: 539 ident: bib19 article-title: Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart publication-title: Aging Cell contributor: fullname: Rabinovitch – volume: 190 start-page: 5649 year: 2013 end-page: 5658 ident: bib38 article-title: Mammalian target of rapamycin regulates IL-10 and resistance to Pseudomonas aeruginosa corneal infection publication-title: J. Immunol. contributor: fullname: Hazlett – volume: 7 start-page: 273 year: 2017 ident: bib3 article-title: Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics publication-title: Front. Oncol. contributor: fullname: Molinski – volume: 148 start-page: e9 year: 2004 ident: bib24 article-title: Oral rapamycin to prevent human coronary stent restenosis: a pilot study publication-title: Am. Heart J. contributor: fullname: Lazen – volume: 55 start-page: 48 year: 1977 end-page: 51 ident: bib9 article-title: Inhibition of the immune response by rapamycin, a new antifungal antibiotic publication-title: Can. J. Physiol. Pharmacol. contributor: fullname: Galet – volume: 426 start-page: 620 year: 2003 ident: bib18 article-title: Genetics: influence of TOR kinase on lifespan in C. elegans publication-title: Nature contributor: fullname: Müller – volume: 16 start-page: 46 year: 2009 end-page: 56 ident: bib26 article-title: Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies publication-title: Cell Death Differ. contributor: fullname: Rubinsztein – volume: 109 start-page: 496 year: 2009 end-page: 503 ident: bib36 article-title: Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice publication-title: J. Pharmacol. Sci. contributor: fullname: Mao – volume: 159 start-page: 217 year: 2002 end-page: 224 ident: bib14 article-title: Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent publication-title: J. Cell Biol. contributor: fullname: Lamb – volume: 5 start-page: 328 year: 2013 end-page: 329 ident: bib23 article-title: Prolonged rapamycin treatment led to beneficial metabolic switch publication-title: Aging (N Y) contributor: fullname: Bartke – volume: 101 start-page: 1542 year: 2016 end-page: 1551 ident: bib33 article-title: Vitamin D3 inhibits Wnt/β-catenin and mTOR signaling pathways in human uterine fibroid cells publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: Halder – volume: 24 start-page: 400 year: 2014 end-page: 406 ident: bib7 article-title: Regulation of mTORC1 by amino acids publication-title: Trends Cell Biol. contributor: fullname: Sabatini – volume: 12 start-page: 218 year: 2007 end-page: 224 ident: bib21 article-title: An anti-aging drug today: from senescence-promoting genes to anti-aging pill publication-title: Drug Discov. Today contributor: fullname: Blagosklonny – volume: 6 start-page: 91 year: 2004 end-page: 99 ident: bib15 article-title: The LKB1 tumor suppressor negatively regulates mTOR signaling publication-title: Canc. Cell contributor: fullname: Cantley – volume: 28 start-page: 465 year: 2015 end-page: 522 ident: bib5 article-title: Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease publication-title: Clin. Microbiol. Rev. contributor: fullname: Yuen – volume: 12 start-page: 1458 year: 2012 end-page: 1468 ident: bib42 article-title: CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages publication-title: Am. J. Transplant. contributor: fullname: Säemann – volume: 18 start-page: 923 year: 2019 end-page: 948 ident: bib49 article-title: Lysosomes as a therapeutic target publication-title: Nat. Rev. Drug Discov. contributor: fullname: Muller – volume: 68 start-page: 7 year: 2016 end-page: 16 ident: bib22 article-title: Biology of healthy aging and longevity publication-title: Rev. Invest. Clin. contributor: fullname: Michan – volume: 20 start-page: 590 issue: 6 year: 2014 ident: 10.1016/j.cbi.2020.109282_bib2 article-title: Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks publication-title: Nat. Med. doi: 10.1038/nm.3595 contributor: fullname: Strittmatter – volume: 6 start-page: 91 issue: 1 year: 2004 ident: 10.1016/j.cbi.2020.109282_bib15 article-title: The LKB1 tumor suppressor negatively regulates mTOR signaling publication-title: Canc. Cell doi: 10.1016/j.ccr.2004.06.007 contributor: fullname: Shaw – volume: 12 start-page: 218 issue: 5–6 year: 2007 ident: 10.1016/j.cbi.2020.109282_bib21 article-title: An anti-aging drug today: from senescence-promoting genes to anti-aging pill publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2007.01.004 contributor: fullname: Blagosklonny – volume: 101 start-page: 1542 issue: 4 year: 2016 ident: 10.1016/j.cbi.2020.109282_bib33 article-title: Vitamin D3 inhibits Wnt/β-catenin and mTOR signaling pathways in human uterine fibroid cells publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2015-3555 contributor: fullname: Al-Hendy – volume: 29 start-page: 3278 issue: 24 year: 2011 ident: 10.1016/j.cbi.2020.109282_bib16 article-title: Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.34.1578 contributor: fullname: Oza – volume: 28 start-page: 465 issue: 2 year: 2015 ident: 10.1016/j.cbi.2020.109282_bib5 article-title: Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease publication-title: Clin. Microbiol. Rev. doi: 10.1128/CMR.00102-14 contributor: fullname: Chan – volume: 161 start-page: 67 issue: 1 year: 2015 ident: 10.1016/j.cbi.2020.109282_bib8 article-title: Nutrient-sensing mechanisms across evolution publication-title: Cell doi: 10.1016/j.cell.2015.02.041 contributor: fullname: Chantranupong – volume: 12 start-page: 6511 issue: 8 year: 2020 ident: 10.1016/j.cbi.2020.109282_bib55 article-title: COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? publication-title: Aging (N Y) contributor: fullname: Sargiacomo – volume: 5 start-page: 2087 issue: 18 year: 2006 ident: 10.1016/j.cbi.2020.109282_bib20 article-title: Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition publication-title: Cell Cycle doi: 10.4161/cc.5.18.3288 contributor: fullname: Blagosklonny – volume: 68 start-page: 7 issue: 1 year: 2016 ident: 10.1016/j.cbi.2020.109282_bib22 article-title: Biology of healthy aging and longevity publication-title: Rev. Invest. Clin. contributor: fullname: Carmona – volume: 181 start-page: 472 issue: 2 year: 2012 ident: 10.1016/j.cbi.2020.109282_bib27 article-title: Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats publication-title: Am. J. Pathol. doi: 10.1016/j.ajpath.2012.04.018 contributor: fullname: Kolosova – volume: 12 issue: 4 year: 2020 ident: 10.1016/j.cbi.2020.109282_bib32 article-title: Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths publication-title: Nutrients doi: 10.3390/nu12040988 contributor: fullname: Grant – volume: 6 start-page: 14 year: 2020 ident: 10.1016/j.cbi.2020.109282_bib57 article-title: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 publication-title: Cell Discov. doi: 10.1038/s41421-020-0153-3 contributor: fullname: Zhou – volume: 8 start-page: 570 issue: 7 year: 2020 ident: 10.1016/j.cbi.2020.109282_bib31 article-title: Vitamin-D and COVID-19: do deficient risk a poorer outcome? publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(20)30183-2 contributor: fullname: Mitchell – volume: 380 start-page: 577 issue: 2 year: 2016 ident: 10.1016/j.cbi.2020.109282_bib54 article-title: Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E) publication-title: Canc. Lett. doi: 10.1016/j.canlet.2015.07.012 contributor: fullname: Husain – volume: 5 start-page: 328 issue: 5 year: 2013 ident: 10.1016/j.cbi.2020.109282_bib23 article-title: Prolonged rapamycin treatment led to beneficial metabolic switch publication-title: Aging (N Y) contributor: fullname: Fang – volume: 509 start-page: 280 year: 2020 ident: 10.1016/j.cbi.2020.109282_bib37 article-title: Cytokine storm induced by SARS-CoV-2 publication-title: Clin. Chim. Acta doi: 10.1016/j.cca.2020.06.017 contributor: fullname: Song – volume: 35 start-page: 321 year: 2015 ident: 10.1016/j.cbi.2020.109282_bib6 article-title: The roles of mTOR complexes in lipid metabolism publication-title: Annu. Rev. Nutr. doi: 10.1146/annurev-nutr-071714-034355 contributor: fullname: Caron – volume: 24 start-page: 400 issue: 7 year: 2014 ident: 10.1016/j.cbi.2020.109282_bib7 article-title: Regulation of mTORC1 by amino acids publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2014.03.003 contributor: fullname: Bar-Peled – volume: 347 start-page: 21 year: 2010 ident: 10.1016/j.cbi.2020.109282_bib50 article-title: Oncogenic mutations of PIK3CA in human cancers publication-title: Curr. Top. Microbiol. Immunol. contributor: fullname: Samuels – volume: 12 start-page: 1458 issue: 6 year: 2012 ident: 10.1016/j.cbi.2020.109282_bib42 article-title: CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages publication-title: Am. J. Transplant. doi: 10.1111/j.1600-6143.2012.04002.x contributor: fullname: Poglitsch – volume: 144 start-page: 251 issue: 1 year: 1990 ident: 10.1016/j.cbi.2020.109282_bib10 article-title: Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin publication-title: J. Immunol. doi: 10.4049/jimmunol.144.1.251 contributor: fullname: Dumont – volume: 22 start-page: 3631 issue: 12 year: 2007 ident: 10.1016/j.cbi.2020.109282_bib44 article-title: Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature publication-title: Nephrol. Dial. Transplant. doi: 10.1093/ndt/gfm420 contributor: fullname: Weiner – volume: 120 start-page: 2858 issue: 8 year: 2010 ident: 10.1016/j.cbi.2020.109282_bib52 article-title: Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus publication-title: J. Clin. Invest. doi: 10.1172/JCI37539 contributor: fullname: Di Nicolantonio – volume: 3 start-page: 673 issue: 8 year: 2004 ident: 10.1016/j.cbi.2020.109282_bib1 article-title: Drug repositioning: identifying and developing new uses for existing drugs publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd1468 contributor: fullname: Ashburn – volume: 4 start-page: 546 issue: 5 year: 2014 ident: 10.1016/j.cbi.2020.109282_bib12 article-title: Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib publication-title: Canc. Discov. doi: 10.1158/2159-8290.CD-13-0353 contributor: fullname: Wagle – volume: 55 start-page: 48 issue: 1 year: 1977 ident: 10.1016/j.cbi.2020.109282_bib9 article-title: Inhibition of the immune response by rapamycin, a new antifungal antibiotic publication-title: Can. J. Physiol. Pharmacol. doi: 10.1139/y77-007 contributor: fullname: Martel – volume: 11 start-page: 654 issue: 4 year: 2011 ident: 10.1016/j.cbi.2020.109282_bib41 article-title: Paradoxical aspects of rapamycin immunobiology in transplantation publication-title: Am. J. Transplant. doi: 10.1111/j.1600-6143.2011.03473.x contributor: fullname: Ferrer – volume: 8 start-page: 314 issue: 2 year: 2016 ident: 10.1016/j.cbi.2020.109282_bib28 article-title: Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts publication-title: Aging (N Y) contributor: fullname: Chiao – volume: 107 start-page: 1664 issue: 12 year: 2003 ident: 10.1016/j.cbi.2020.109282_bib25 article-title: Rapamycin attenuates load-induced cardiac hypertrophy in mice publication-title: Circulation doi: 10.1161/01.CIR.0000057979.36322.88 contributor: fullname: Shioi – volume: 460 start-page: 392 issue: 7253 year: 2009 ident: 10.1016/j.cbi.2020.109282_bib17 article-title: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice publication-title: Nature doi: 10.1038/nature08221 contributor: fullname: Harrison – volume: 8 start-page: 4822 issue: 11 year: 2016 ident: 10.1016/j.cbi.2020.109282_bib40 article-title: Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells publication-title: Am. J. Trans. Res. contributor: fullname: Ekshyyan – start-page: 1 year: 2020 ident: 10.1016/j.cbi.2020.109282_bib56 article-title: An update on current therapeutic drugs treating COVID-19 publication-title: Curr. Pharmacol. Rep. contributor: fullname: Wu – volume: 5 year: 2016 ident: 10.1016/j.cbi.2020.109282_bib48 article-title: Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity publication-title: Elife doi: 10.7554/eLife.11058 contributor: fullname: Carroll – volume: 153 start-page: 1194 issue: 6 year: 2013 ident: 10.1016/j.cbi.2020.109282_bib30 article-title: The hallmarks of aging publication-title: Cell doi: 10.1016/j.cell.2013.05.039 contributor: fullname: López-Otín – volume: 63 start-page: 4472 issue: 15 year: 2003 ident: 10.1016/j.cbi.2020.109282_bib39 article-title: Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas publication-title: Canc. Res. contributor: fullname: Nepomuceno – volume: 7 start-page: 273 year: 2017 ident: 10.1016/j.cbi.2020.109282_bib3 article-title: Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics publication-title: Front. Oncol. doi: 10.3389/fonc.2017.00273 contributor: fullname: Hernandez – volume: 150 start-page: 1196 issue: 6 year: 2012 ident: 10.1016/j.cbi.2020.109282_bib47 article-title: Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1 publication-title: Cell doi: 10.1016/j.cell.2012.07.032 contributor: fullname: Bar-Peled – volume: 90 start-page: 8924 issue: 19 year: 2016 ident: 10.1016/j.cbi.2020.109282_bib4 article-title: Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion publication-title: J. Virol. doi: 10.1128/JVI.01429-16 contributor: fullname: Coleman – volume: 98 start-page: 10314 issue: 18 year: 2001 ident: 10.1016/j.cbi.2020.109282_bib13 article-title: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.171076798 contributor: fullname: Neshat – volume: 109 start-page: 496 issue: 4 year: 2009 ident: 10.1016/j.cbi.2020.109282_bib36 article-title: Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice publication-title: J. Pharmacol. Sci. doi: 10.1254/jphs.08215FP contributor: fullname: Chang – volume: 426 start-page: 620 issue: 6967 year: 2003 ident: 10.1016/j.cbi.2020.109282_bib18 article-title: Genetics: influence of TOR kinase on lifespan in C. elegans publication-title: Nature doi: 10.1038/426620a contributor: fullname: Vellai – volume: 10 start-page: 1888 issue: 12 year: 2011 ident: 10.1016/j.cbi.2020.109282_bib34 article-title: Vitamin D: a new player in the world of mTOR signaling publication-title: Cell Cycle doi: 10.4161/cc.10.12.15620 contributor: fullname: Lisse – volume: 148 start-page: e9 issue: 2 year: 2004 ident: 10.1016/j.cbi.2020.109282_bib24 article-title: Oral rapamycin to prevent human coronary stent restenosis: a pilot study publication-title: Am. Heart J. doi: 10.1016/j.ahj.2004.03.046 contributor: fullname: Guarda – volume: 4 start-page: 554 issue: 5 year: 2014 ident: 10.1016/j.cbi.2020.109282_bib11 article-title: A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity publication-title: Canc. Discov. doi: 10.1158/2159-8290.CD-13-0929 contributor: fullname: Grabiner – volume: 28 start-page: 126 issue: 3 year: 2014 ident: 10.1016/j.cbi.2020.109282_bib46 article-title: Strategies for the management of adverse events associated with mTOR inhibitors publication-title: Transplant. Rev. doi: 10.1016/j.trre.2014.03.002 contributor: fullname: Kaplan – volume: 159 start-page: 217 issue: 2 year: 2002 ident: 10.1016/j.cbi.2020.109282_bib14 article-title: Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent publication-title: J. Cell Biol. doi: 10.1083/jcb.jcb.200206108 contributor: fullname: Jaeschke – volume: 190 start-page: 5649 issue: 11 year: 2013 ident: 10.1016/j.cbi.2020.109282_bib38 article-title: Mammalian target of rapamycin regulates IL-10 and resistance to Pseudomonas aeruginosa corneal infection publication-title: J. Immunol. doi: 10.4049/jimmunol.1203094 contributor: fullname: Foldenauer – volume: 30 start-page: 3222 issue: 29 year: 2011 ident: 10.1016/j.cbi.2020.109282_bib51 article-title: PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs publication-title: Oncogene doi: 10.1038/onc.2011.42 contributor: fullname: Weigelt – volume: 13 start-page: 529 issue: 3 year: 2014 ident: 10.1016/j.cbi.2020.109282_bib19 article-title: Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart publication-title: Aging Cell doi: 10.1111/acel.12203 contributor: fullname: Dai – volume: 95 start-page: 247 issue: 1 year: 2011 ident: 10.1016/j.cbi.2020.109282_bib35 article-title: Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2010.07.1041 contributor: fullname: Sharan – volume: 18 start-page: 923 issue: 12 year: 2019 ident: 10.1016/j.cbi.2020.109282_bib49 article-title: Lysosomes as a therapeutic target publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-019-0036-1 contributor: fullname: Bonam – volume: 369 start-page: 1210 issue: 6508 year: 2020 ident: 10.1016/j.cbi.2020.109282_bib43 article-title: Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans publication-title: Science doi: 10.1126/science.abc6261 contributor: fullname: Arunachalam – volume: 12 start-page: 177 issue: 2 year: 2013 ident: 10.1016/j.cbi.2020.109282_bib45 article-title: Adverse events associated with mTOR inhibitors publication-title: Expet Opin. Drug Saf. doi: 10.1517/14740338.2013.752814 contributor: fullname: Pallet – volume: 16 start-page: 46 issue: 1 year: 2009 ident: 10.1016/j.cbi.2020.109282_bib26 article-title: Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies publication-title: Cell Death Differ. doi: 10.1038/cdd.2008.110 contributor: fullname: Sarkar – volume: 8 start-page: 788 year: 2017 ident: 10.1016/j.cbi.2020.109282_bib53 article-title: mTOR as a key regulator in maintaining skeletal muscle mass publication-title: Front. Physiol. doi: 10.3389/fphys.2017.00788 contributor: fullname: Yoon – volume: 169 start-page: 361 issue: 2 year: 2017 ident: 10.1016/j.cbi.2020.109282_bib29 article-title: mTOR signaling in growth, metabolism, and disease publication-title: Cell doi: 10.1016/j.cell.2017.03.035 contributor: fullname: Saxton |
SSID | ssj0000240 |
Score | 2.53715 |
SecondaryResourceType | review_article |
Snippet | The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global... |
SourceID | pubmedcentral crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 109282 |
SubjectTerms | Betacoronavirus - isolation & purification Betacoronavirus - physiology Cell Proliferation - drug effects Coronavirus Infections - drug therapy Coronavirus Infections - pathology Coronavirus Infections - virology COVID-19 Cytokines - metabolism Drug Repositioning Drug repurposing Gene Expression - drug effects Humans mTOR Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - pathology Pneumonia, Viral - virology Rapamycin SARS-CoV-2 Sirolimus - pharmacology Sirolimus - therapeutic use TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - metabolism Virus Replication - drug effects |
Title | Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19 |
URI | https://dx.doi.org/10.1016/j.cbi.2020.109282 https://www.ncbi.nlm.nih.gov/pubmed/33031791 https://pubmed.ncbi.nlm.nih.gov/PMC7536130 |
Volume | 331 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB5EEb2Ib9cXOYgHodq0SZoe11VZFRVEZW8lSVOtsN1lXQ9e_O1O-ljdi4K3Nk3bMAnzSL75BuCABcZotCNenFrtMWVjT0nLPCGYoBmXMS9Jkm5uRfeRXfV4bwY6TS6Mg1XWur_S6aW2rltOammeDPPc5fj6cRDF7hwRnYSw5zLY0Rjhmj7-_IZ5OA6vppqa692cbJYYL6NzDBGDklQpkMGftmkaN_nDEF0sw1LtQZJ2NcgVmLHFKqy1C4ye-x_kkJSYznKzfBXmT5urhU5T2W0N7u7RQvY_TF4Q9UYUGQ7GDjOEHx3ZIQp-8GZJOnp_JsblvLgtAYKuLUFXkUxw6WSQkc7d0-WZR-N1eLw4f-h0vbqwgmcYp2NPSIFRmol8bQKestQoyX0_1UxHkaGBsOhGZUpxRi02igytWyaCzKdSc6pDFW7AbDEo7BYQaqKYxlxJ7YdMGy2Z0tRKoaVwNbGyFhw1Ik2GFX9G0gDLXhOUf-Lkn1TybwFrhJ5MLYIE9ftvr21W8zL5Q4iG2fGutiCamrFJB0eqPf2kyF9Kcm0M31xItf2_oezAorurkhV3YXY8erd76LWM9X65LPdhrn153b39Au-m6lQ |
link.rule.ids | 230,315,786,790,891,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NT9swFH-CogkuE-OzY2w-oB2QImLHdpxjV0DtgCJNgHqLbMdhmdS0KuXAf89zPsp6YdJukR0n1s_W-7B_7z2AE86sNahHgiRzJuDaJYFWjgdScklzoRJRJUm6GcnBPf85FuM16LexMJ5W2cj-WqZX0rppOWvQPJsVhY_xDRMWJ_4eEY2EaLwOG1zElHdgoze8GozeBDLjYVtQzQ9oLzcrmpc1BXqJrMqrxBT7p3papU7-pYsut-FjY0SSXj3PT7Dmyh3Y7ZXoQE9eyHdS0Tqr8_Id-PCjfdrst8XdduH2FyrJyYstSqKfiCaz6cLThvCjczdD7KdPjmTz50difdiLPxUgaN0StBbJkppOpjnp3z4MzwOa7MH95cVdfxA0tRUCywVdBFJJdNRsHBrLRMYzq5UIw8xwE8eWMunQksq1Fpw6bJQ5KrhcsjykyghqIh3tQ6eclu4QCLVxQhOhlQkjbqxRXBvqlDRK-rJYeRdOW0jTWZ1CI225ZX9SxD_1-Kc1_l3gLejpyj5IUcS_N-ygXpflHyLUzT71ahfilRVbvuDzaq_2lMXvKr82enDeq_r8f1P5BpuDu5vr9Ho4ujqCLd9Txy5-gc5i_uyO0YhZmK_NJn0FDjHtCg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rapamycin+as+a+potential+repurpose+drug+candidate+for+the+treatment+of+COVID-19&rft.jtitle=Chemico-biological+interactions&rft.au=Husain%2C+Amjad&rft.au=Byrareddy%2C+Siddappa+N.&rft.date=2020-11-01&rft.pub=Elsevier+B.V&rft.issn=0009-2797&rft.eissn=1872-7786&rft.volume=331&rft_id=info:doi/10.1016%2Fj.cbi.2020.109282&rft.externalDocID=S000927972031053X |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-2797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-2797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-2797&client=summon |